Altris AI

📍 Chicago, United States🗓 Founded 2018👥 34 employees💰 Last funded Jan 2024
Software Development🌐 altris.ai
Website LinkedIn
Altris AI is a Decision Making Support for OCT that detects, quantifies, and tracks 70 + retina pathologies on OCT scans, including early glaucoma. The system is FDA-cleared (510K), CE-certified, and HIPAA-compliant. More than 500 eye care specialists use Altris AI to enhance their OCT workflow, enable early detection of many pathologies, and assist with diagnostic decision-making. It results in better outcomes for their patients and patient loyalty. AI-powered glaucoma risk assessment modules ( built on the basis of Optic Disc parameters analysis + GCC asymmetry analysis) are created for timely detection of this vision-threatening condition has no analogues on the market.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2018
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Spain
1
United Kingdom
1
Frequently asked questions
Who invested in Altris AI?
Altris AI has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Altris AI last raise funding?
The most recent investment in Altris AI recorded on gritt.io was in January 2024.
When was Altris AI founded?
Altris AI was founded in 2018.
What industry is Altris AI in?
Altris AI operates in Software Development. Find similar Software Development investors on gritt.io.
Where is Altris AI based?
Altris AI is headquartered in Chicago, United States.